Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC)

Tomomitsu Tahara, Tomoyuki Shibata, Masakatsu Nakamura, Hiromi Yamashita, Daisuke Yoshioka, Masaaki Okubo, Naoko Maruyama, Toshiaki Kamano, Yoshio Kamiya, Hiroshi Fujita, Yoshihito Nakagawa, Mitsuo Nagasaka, Masami Iwata, Kazuya Takahama, Makoto Watanabe, Hiroshi Nakano, Ichiro Hirata, Tomiyasu Arisawa

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Tryptase acting at protease-activated receptor 2 (PAR2) contributes to the pathogenesis of Inflammatory bowel diseases (IBDs). DNA methylation has been shown to be an important mechanism in gene silencing. We attempted to clarify the relationship between the promoter methylation of PAR2 and ulcerative colitis (UC). 84 UC patients enrolled in the study. UC patients were classified by disease behavior, severity and extent of disease. For rectal inflammatory mucosal specimens from all the patients, and normal terminal ileum from 23 patients, promoter methylation of PAR2 gene was quantified by digital densitographic analysis following to methylation-specific polymerase chain reaction (MSP). The mean methylation levels of the PAR2 gene in all 84 subjects was 38.4 ± 19.6%. Although mean methylation levels in rectal inflammatory mucosa, and paired normal terminal ileum did not vary, methylation levels of PAR2 gene was significantly higher in total colitis than rectal colitis (total colitis vs. rectal colitis; 42.9 ± 19.6% vs. 34.5 ± 18.9%, P = 0.046). The higher methylation levels were also associated with Steroid-dependent (P = 0.002) and refractory (P = 0.007) UC. Our data suggest that PAR2 methylation status in rectal mucosa correlates with more severe disease phenotypes of UC.

Original languageEnglish
Pages (from-to)125-130
Number of pages6
JournalClinical and Experimental Medicine
Volume9
Issue number2
DOIs
Publication statusPublished - 01-06-2009

Fingerprint

Proteinase-Activated Receptors
PAR-2 Receptor
Methylation
Ulcerative Colitis
Phenotype
Colitis
Genes
Ileum
Mucous Membrane
Tryptases
Polymerase chain reaction
Gene Silencing
DNA Methylation
Inflammatory Bowel Diseases
Refractory materials
Steroids
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Tahara, Tomomitsu ; Shibata, Tomoyuki ; Nakamura, Masakatsu ; Yamashita, Hiromi ; Yoshioka, Daisuke ; Okubo, Masaaki ; Maruyama, Naoko ; Kamano, Toshiaki ; Kamiya, Yoshio ; Fujita, Hiroshi ; Nakagawa, Yoshihito ; Nagasaka, Mitsuo ; Iwata, Masami ; Takahama, Kazuya ; Watanabe, Makoto ; Nakano, Hiroshi ; Hirata, Ichiro ; Arisawa, Tomiyasu. / Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC). In: Clinical and Experimental Medicine. 2009 ; Vol. 9, No. 2. pp. 125-130.
@article{01bee381d2d14077a4671a8930b90e40,
title = "Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC)",
abstract = "Tryptase acting at protease-activated receptor 2 (PAR2) contributes to the pathogenesis of Inflammatory bowel diseases (IBDs). DNA methylation has been shown to be an important mechanism in gene silencing. We attempted to clarify the relationship between the promoter methylation of PAR2 and ulcerative colitis (UC). 84 UC patients enrolled in the study. UC patients were classified by disease behavior, severity and extent of disease. For rectal inflammatory mucosal specimens from all the patients, and normal terminal ileum from 23 patients, promoter methylation of PAR2 gene was quantified by digital densitographic analysis following to methylation-specific polymerase chain reaction (MSP). The mean methylation levels of the PAR2 gene in all 84 subjects was 38.4 ± 19.6{\%}. Although mean methylation levels in rectal inflammatory mucosa, and paired normal terminal ileum did not vary, methylation levels of PAR2 gene was significantly higher in total colitis than rectal colitis (total colitis vs. rectal colitis; 42.9 ± 19.6{\%} vs. 34.5 ± 18.9{\%}, P = 0.046). The higher methylation levels were also associated with Steroid-dependent (P = 0.002) and refractory (P = 0.007) UC. Our data suggest that PAR2 methylation status in rectal mucosa correlates with more severe disease phenotypes of UC.",
author = "Tomomitsu Tahara and Tomoyuki Shibata and Masakatsu Nakamura and Hiromi Yamashita and Daisuke Yoshioka and Masaaki Okubo and Naoko Maruyama and Toshiaki Kamano and Yoshio Kamiya and Hiroshi Fujita and Yoshihito Nakagawa and Mitsuo Nagasaka and Masami Iwata and Kazuya Takahama and Makoto Watanabe and Hiroshi Nakano and Ichiro Hirata and Tomiyasu Arisawa",
year = "2009",
month = "6",
day = "1",
doi = "10.1007/s10238-008-0025-x",
language = "English",
volume = "9",
pages = "125--130",
journal = "Clinical and Experimental Medicine",
issn = "1591-8890",
publisher = "Springer-Verlag Italia",
number = "2",

}

Tahara, T, Shibata, T, Nakamura, M, Yamashita, H, Yoshioka, D, Okubo, M, Maruyama, N, Kamano, T, Kamiya, Y, Fujita, H, Nakagawa, Y, Nagasaka, M, Iwata, M, Takahama, K, Watanabe, M, Nakano, H, Hirata, I & Arisawa, T 2009, 'Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC)', Clinical and Experimental Medicine, vol. 9, no. 2, pp. 125-130. https://doi.org/10.1007/s10238-008-0025-x

Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC). / Tahara, Tomomitsu; Shibata, Tomoyuki; Nakamura, Masakatsu; Yamashita, Hiromi; Yoshioka, Daisuke; Okubo, Masaaki; Maruyama, Naoko; Kamano, Toshiaki; Kamiya, Yoshio; Fujita, Hiroshi; Nakagawa, Yoshihito; Nagasaka, Mitsuo; Iwata, Masami; Takahama, Kazuya; Watanabe, Makoto; Nakano, Hiroshi; Hirata, Ichiro; Arisawa, Tomiyasu.

In: Clinical and Experimental Medicine, Vol. 9, No. 2, 01.06.2009, p. 125-130.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC)

AU - Tahara, Tomomitsu

AU - Shibata, Tomoyuki

AU - Nakamura, Masakatsu

AU - Yamashita, Hiromi

AU - Yoshioka, Daisuke

AU - Okubo, Masaaki

AU - Maruyama, Naoko

AU - Kamano, Toshiaki

AU - Kamiya, Yoshio

AU - Fujita, Hiroshi

AU - Nakagawa, Yoshihito

AU - Nagasaka, Mitsuo

AU - Iwata, Masami

AU - Takahama, Kazuya

AU - Watanabe, Makoto

AU - Nakano, Hiroshi

AU - Hirata, Ichiro

AU - Arisawa, Tomiyasu

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Tryptase acting at protease-activated receptor 2 (PAR2) contributes to the pathogenesis of Inflammatory bowel diseases (IBDs). DNA methylation has been shown to be an important mechanism in gene silencing. We attempted to clarify the relationship between the promoter methylation of PAR2 and ulcerative colitis (UC). 84 UC patients enrolled in the study. UC patients were classified by disease behavior, severity and extent of disease. For rectal inflammatory mucosal specimens from all the patients, and normal terminal ileum from 23 patients, promoter methylation of PAR2 gene was quantified by digital densitographic analysis following to methylation-specific polymerase chain reaction (MSP). The mean methylation levels of the PAR2 gene in all 84 subjects was 38.4 ± 19.6%. Although mean methylation levels in rectal inflammatory mucosa, and paired normal terminal ileum did not vary, methylation levels of PAR2 gene was significantly higher in total colitis than rectal colitis (total colitis vs. rectal colitis; 42.9 ± 19.6% vs. 34.5 ± 18.9%, P = 0.046). The higher methylation levels were also associated with Steroid-dependent (P = 0.002) and refractory (P = 0.007) UC. Our data suggest that PAR2 methylation status in rectal mucosa correlates with more severe disease phenotypes of UC.

AB - Tryptase acting at protease-activated receptor 2 (PAR2) contributes to the pathogenesis of Inflammatory bowel diseases (IBDs). DNA methylation has been shown to be an important mechanism in gene silencing. We attempted to clarify the relationship between the promoter methylation of PAR2 and ulcerative colitis (UC). 84 UC patients enrolled in the study. UC patients were classified by disease behavior, severity and extent of disease. For rectal inflammatory mucosal specimens from all the patients, and normal terminal ileum from 23 patients, promoter methylation of PAR2 gene was quantified by digital densitographic analysis following to methylation-specific polymerase chain reaction (MSP). The mean methylation levels of the PAR2 gene in all 84 subjects was 38.4 ± 19.6%. Although mean methylation levels in rectal inflammatory mucosa, and paired normal terminal ileum did not vary, methylation levels of PAR2 gene was significantly higher in total colitis than rectal colitis (total colitis vs. rectal colitis; 42.9 ± 19.6% vs. 34.5 ± 18.9%, P = 0.046). The higher methylation levels were also associated with Steroid-dependent (P = 0.002) and refractory (P = 0.007) UC. Our data suggest that PAR2 methylation status in rectal mucosa correlates with more severe disease phenotypes of UC.

UR - http://www.scopus.com/inward/record.url?scp=67349285075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349285075&partnerID=8YFLogxK

U2 - 10.1007/s10238-008-0025-x

DO - 10.1007/s10238-008-0025-x

M3 - Article

C2 - 19184329

AN - SCOPUS:67349285075

VL - 9

SP - 125

EP - 130

JO - Clinical and Experimental Medicine

JF - Clinical and Experimental Medicine

SN - 1591-8890

IS - 2

ER -